StreetInsider.com News Articles

Piper Sandler on Biotechnology: 'Look for Biotech to Outperform through YE:26'

Tue, 01 Sep 2026 09:07:24 -0400

Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.

The analyst commented: "Look for Biotech to Outperform through YE:26 with Multiple Value Driving Events; Biotech had a strong summer exemplified by Moderna's (MRNA) 177% single day move on positive INTERpath-001 data. We expect Biotech to finish the year strong driven by commercial growth, validating clinical data, unprecedented innovation and continued M&A. We look for growth of Alnylam's (ALNY) AMVUTTRA, Legend's (LEGN) CARVYKTI and Mesoblast's (MESO) Ryoncil. Capricor (CAPR) has a November 22nd PDUFA date for deromicel in DMD, Moderna will present intismeran data, Arrowhead (ARWR) will file the sNDA for

Piper Sandler on Biotechnology: 'Look for Biotech to Outperform through YE:26'

Tue, 01 Sep 2026 09:07:24 -0400

Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.

Piper Sandler on Biotechnology: 'Look for Biotech to Outperform through YE:26'

Tue, 01 Sep 2026 09:07:24 -0400

Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.

Piper Sandler on Biotechnology: 'Look for Biotech to Outperform through YE:26'

Tue, 01 Sep 2026 09:07:24 -0400

Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.

Piper Sandler on Biotechnology: 'Look for Biotech to Outperform through YE:26'

Tue, 01 Sep 2026 09:07:24 -0400

Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.

Piper Sandler on Biotechnology: 'Look for Biotech to Outperform through YE:26'

Tue, 01 Sep 2026 09:07:24 -0400

Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.

Piper Sandler on Biotechnology: 'Look for Biotech to Outperform through YE:26'

Tue, 01 Sep 2026 09:07:24 -0400

Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.

Piper Sandler on Biotechnology: 'Look for Biotech to Outperform through YE:26'

Tue, 01 Sep 2026 09:07:24 -0400

Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.

Piper Sandler on Biotechnology: 'Look for Biotech to Outperform through YE:26'

Tue, 01 Sep 2026 09:07:24 -0400

Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.

Piper Sandler on Biotechnology: 'Look for Biotech to Outperform through YE:26'

Tue, 01 Sep 2026 09:07:24 -0400

Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.

Piper Sandler on Biotechnology: 'Look for Biotech to Outperform through YE:26'

Tue, 01 Sep 2026 09:07:24 -0400

Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.

Piper Sandler on Biotechnology: 'Look for Biotech to Outperform through YE:26'

Tue, 01 Sep 2026 09:07:24 -0400

Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.

Piper Sandler on Biotechnology: 'Look for Biotech to Outperform through YE:26'

Tue, 01 Sep 2026 09:07:24 -0400

Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.

Piper Sandler on Biotechnology: 'Look for Biotech to Outperform through YE:26'

Tue, 01 Sep 2026 09:07:24 -0400

Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.

Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences

Tue, 01 Sep 2026 07:00:00 -0400

BOSTON, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that management will participate in the following investor conferences:

Wells Fargo 21st Annual Healthcare Conference (Boston, MA) – Markus Warmuth, M.D., Chief Executive Officer, to participate in a fireside chat, September 10, 2026, at 12:45 p.m. ET
Morgan Stanley 24th Annual Global Healthcare Conference (New York, NY) – September 14, 2026

A webcast of the fireside chat will be accessible via the “Events &

Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences

Tue, 01 Sep 2026 07:00:00 -0400

Wells Fargo 21st Annual Healthcare Conference (Boston, MA) – Markus Warmuth, M.D., Chief Executive Officer, to participate in a fireside chat, September 10, 2026, at 12:45 p.m. ET
Morgan Stanley 24th Annual Global Healthcare Conference (New York, NY) – September 14, 2026

A webcast of the fireside chat will be accessible via the “Events &

Monte Rosa doses first patient in phase 2 prostate cancer study

Mon, 24 Aug 2026 07:00:17 -0400

Monte Rosa Therapeutics (Nasdaq: GLUE) announced that the first patient has been dosed in MODeFIRe-1, a Phase 2 clinical trial evaluating MRT-2359 in combination with apalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) with androgen receptor (AR) mutations.

The study, identified as NCT07745361 on clinicaltrials.gov, will enroll up to 25 patients using a Simon's two-stage design. MRT-2359 will be administered orally at 0.5 mg on a 21 days on, 7 days off schedule over 28-day cycles, combined with apalutamide, a second-generation AR inhibitor. Eligible patients must have confirmed AR mutations and prior treatment with a second-generation AR inhibitor.

Study endpoints include

Monte Rosa Therapeutics Announces First Patient Dosed in MODeFIRe-1, a Phase 2 Study of MRT-2359 in Combination with Apalutamide in Patients with AR Mutation-Positive Metastatic Castration-Resistant P

Mon, 24 Aug 2026 07:00:00 -0400

Study will evaluate PSA and RECIST response, duration of response, radiographic progression-free survival (rPFS), and safety

Updated data from the initial Phase 1/2 study of MRT-2359 plus enzalutamide in patients with advanced CRPC expected by end of year

BOSTON, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that the first patient has been dosed in MODeFIRe-1 (clinicaltrials.gov identifier NCT07745361), a Phase 2 study evaluating MRT-2359 in combination with apalutamide, a second-generation androgen receptor (AR) inhibitor, in

Monte Rosa Therapeutics Announces First Patient Dosed in MODeFIRe-1, a Phase 2 Study of MRT-2359 in Combination with Apalutamide in Patients with AR Mutation-Positive Metastatic Castration-Resistant P

Mon, 24 Aug 2026 07:00:00 -0400

Study will evaluate PSA and RECIST response, duration of response, radiographic progression-free survival (rPFS), and safety

Updated data from the initial Phase 1/2 study of MRT-2359 plus enzalutamide in patients with advanced CRPC expected by end of year

TD Cowen Assumes Monte Rosa Therapeutics (GLUE) at Buy

Sat, 22 Aug 2026 07:54:31 -0400

TD Cowen analyst Tyler Van Buren assumes coverage on Monte Rosa Therapeutics (NASDAQ: GLUE) with a Buy rating.

For an analyst ratings summary and ratings history on Monte Rosa Therapeutics click here. For more ratings news on Monte Rosa Therapeutics click here.

Shares of Monte Rosa Therapeutics closed at $14.30 yesterday.

Form SCHEDULE 13G/A Monte Rosa Therapeutics, Filed by: MONTANOVA CAPITAL, LLC

Fri, 14 Aug 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260814/26931407.html

Form SCHEDULE 13G/A Monte Rosa Therapeutics, Filed by: MONTANOVA CAPITAL, LLC

Fri, 14 Aug 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260814/26931407.html

Form SCHEDULE 13G Monte Rosa Therapeutics, Filed by: Vestal Point Capital, LP

Fri, 14 Aug 2026 16:17:00 -0400

si-local-file:///var/storage/secattach/20260814/26930678.html

Form SCHEDULE 13G Monte Rosa Therapeutics, Filed by: Vestal Point Capital, LP

Fri, 14 Aug 2026 16:17:00 -0400

si-local-file:///var/storage/secattach/20260814/26930678.html

Monte Rosa Therapeutics (GLUE) PT Lowered to $27 at JPMorgan

Fri, 07 Aug 2026 09:40:43 -0400

JPMorgan analyst Brian Cheng lowered the price target on Monte Rosa Therapeutics (NASDAQ: GLUE) to $27.00 (from $31.00) while maintaining a Overweight rating.